Master10
Public Health, Nutrition & Epidemics20 Concepts & Facts

Global Mpox Vaccine Stockpile: Outbreak Response, Access Mechanism & Vaccines

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy
The Global Mpox Vaccine Stockpile represents an emergency multilateral coordination framework created to pool, allocate, and distribute licensed vaccines against the monkeypox virus during cross-border health emergencies. Mpox is caused by the monkeypox virus, an enveloped, double-stranded DNA virus belonging to the Orthopoxvirus genus within the Poxviridae family. Genomic surveillance distinguishes two major evolutionary lineages: Clade I, historically endemic to the Congo Basin of Central Africa with reported case fatality rates up to ten percent, and Clade II, endemic to West Africa, which drove the global outbreak starting in 2022 with a lower case fatality rate. On 14 August 2024, the Director-General of the World Health Organization declared the surge of mpox in the Democratic Republic of the Congo and neighbouring African countries a Public Health Emergency of International Concern under the International Health Regulations of 2005.

The operational architecture of the stockpile relies on the Access and Allocation Mechanism established jointly by the World Health Organization, the Africa Centres for Disease Control and Prevention, UNICEF, Gavi, and the Coalition for Epidemic Preparedness Innovations. This mechanism pools donated vaccine supplies and direct donor financing to prevent competitive bilateral procurement that previously disadvantaged low-income nations. Procurement focuses on two principal formulations: Modified Vaccinia Ankara-Bavarian Nordic, a third-generation non-replicating viral vector vaccine administered subcutaneously in a two-dose schedule, and LC16m8, a freeze-dried live attenuated vaccine administered through a bifurcated needle. Allocation decisions follow objective epidemiological criteria, prioritizing ring vaccination around confirmed index cases, exposed healthcare workers, laboratory personnel, and immunocompromised demographics in active transmission zones.

For civil services and competitive examinations, the mpox stockpile illustrates the evolving intersection of international health regulations, global biomedical supply chain equity, and zoonotic outbreak management. The virus transmits through direct contact with infectious lesions, bodily fluids, respiratory droplets during prolonged close contact, and contaminated fomites. Lymphadenopathy remains a defining clinical diagnostic marker that differentiates mpox from smallpox and varicella. Effective field deployment requires strict ultralow temperature cold chain logistics, decentralized diagnostic polymerase chain reaction infrastructure, and community surveillance to interrupt transmission chains before regional epidemics cross international borders.

Key Concepts & Self-Assessment20 Key Facts

Review key What Is the Global Mpox Vaccine Stockpile and How Will It Improve Outbreak Response? exam facts and rate your mastery to track revision.

Progress: 0/20 Rated 0 Mastered 0 Review Later
#1
The World Health Organization declared mpox a Public Health Emergency of International Concern on 14 August 2024 under the International Health Regulations 2005.
#2
The Africa Centres for Disease Control and Prevention declared mpox a Public Health Emergency of Continental Security on 13 August 2024.
#3
Monkeypox virus is an enveloped, double-stranded DNA virus belonging to the Orthopoxvirus genus in the Poxviridae family.
#4
Genomic classification separates mpox into Clade I (subclades Ia and Ib) found in Central Africa and Clade II (subclades IIa and IIb) originating in West Africa.
#5
Clade Ib represents a newly emerged lineage characterized by sustained human-to-human transmission, first identified in South Kivu, Democratic Republic of the Congo.
#6
The Access and Allocation Mechanism was co-founded by WHO, Africa CDC, Gavi, UNICEF, and CEPI to manage equitable distribution of mpox countermeasures.
#7
MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) is a non-replicating attenuated vaccinia vaccine approved for adults aged 18 and older in a 2-dose regimen.
#8
WHO granted its first mpox prequalification to the MVA-BN vaccine on 13 September 2024, facilitating procurement by UN agencies and Gavi.
#9
LC16m8 is a minimally replicating, attenuated live vaccinia vaccine developed in Japan and administered via scarification using a bifurcated needle.
#10
Lymphadenopathy (swollen lymph nodes in the neck, armpits, or groin) is the primary clinical hallmark that distinguishes mpox from smallpox and chickenpox.
#11
The incubation period for mpox ranges from 5 to 21 days, followed by a prodromal febrile phase lasting 1 to 4 days before cutaneous eruptions emerge.
#12
The skin rash progresses systematically through five morphological stages: macules, papules, vesicles, umbilicated pustules, and crusts that desquamate.
#13
Real-time Polymerase Chain Reaction testing of swab samples taken directly from skin lesion exudate or crusts is the gold standard diagnostic method.
#14
Serology and antibody detection are not reliable for specific mpox diagnosis due to antigenic cross-reactivity among all Orthopoxviruses.
#15
Tecovirimat (TPOXX) is an antiviral therapeutic that inhibits the VP37 envelope protein of orthopoxviruses, evaluated for treating severe clinical presentations.
#16
Natural animal reservoirs for monkeypox virus in Africa include rope squirrels, tree squirrels, Gambian pouched rats, and non-human primates.
#17
Historical smallpox vaccination using early-generation vaccinia formulations provides approximately 85 percent cross-protective immunity against mpox.
#18
Post-exposure prophylaxis with MVA-BN is recommended within 4 days of contact with a confirmed case to prevent disease onset, or up to 14 days to reduce severity.
#19
In India, the National Centre for Disease Control and the Indian Council of Medical Research serve as the apex surveillance and laboratory testing authorities for mpox.
#20
The Emergency Use Listing procedure of the World Health Organization expedites international availability of unlicensed medical products during global health crises.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight
The Global Mpox Vaccine Stockpile is an emergency health framework designed to pool and fairly distribute vaccines during monkeypox outbreaks. Caused by an enveloped double-stranded DNA virus in the Orthopoxvirus family, mpox spreads through close contact, causing fever, painful skin eruptions, and swollen lymph nodes. Following the emergence of the virulent Clade Ib strain in Central Africa, international health agencies organized this stockpile to deliver vaccines rapidly to communities facing health emergencies.
In UPSC Prelims and State PSC public health questions, distinguish mpox from smallpox and chickenpox: lymphadenopathy (swollen lymph nodes) is the unique clinical hallmark of mpox. Note that WHO declared mpox a Public Health Emergency of International Concern in August 2024. Remember key vaccines: MVA-BN, an attenuated vaccine prequalified by WHO in September 2024, and Japan’s LC16m8. A typical test trap confuses diagnostics: PCR testing of lesion fluid is the gold standard, not antibody tests.

Related Knowledge Topics to Discover

Looking for more GK practice?

Explore 52,789+ questions across 65 General Knowledge categories.

Open Interactive Search